English (UK)
中文版Qin Liu
JIANGBEI NEW AREA IS THE 13rd national new area，and 1st in jiangsu province.
Jiangbei New area
managerMr. Allan Liu
TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.
TF Capital
Vice PresidentMs. Annie Liu
Founded in 2016 with over $800 million assets under management, Terra Magnum Capital Partners ("TMCP" or "the firm") is a China-focused private equity firm specialized in both direct investments and fund investments.
Terra Magnum Capital
Analyst
Dr. Akira Liu
AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Responsive Web Design powered by 